Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Eli Lilly and Company (NYSE: LLY ) and Verve Therapeutics, Inc. (NASDAQ: VERV ) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Eli Lilly and Company (NYSE: LLY) is one of the best long term low volatility stocks to buy now. In a report released on July ...

President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports. Lilly's margins could be negatively ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.